RESUMEN
A rapid, straightforward, and sensitive approach to quantifying enantiomeric barbiturates in serum was developed by integrating ultrasound-assisted dispersive liquid-liquid microextraction (UA-DLLME) with large-volume sample stacking (LVSS) in capillary electrophoresis (CE). UA-DLLME was employed for sample preparation, and on-column preconcentration by using LVSS with polarity switching was implemented to enhance sensitivity. We thoroughly investigated and optimized various parameters influencing extraction and stacking to achieve optimal detection performance with the highest enrichment efficiencies. Under optimal extraction conditions (injection of a mixed solution containing 40 µL of CHCl3 and 200 µL of tetrahydrofuran into 1 mL of a sample solution at pH 10.0), LVSS was performed using 600 mM Tris-boric acid (pH 9.5) containing 35 mM hydroxypropyl-ß-cyclodextrin and sodium taurodeoxycholate hydrate. A voltage of 20 kV was applied and a preinjection water plug was loaded at a height of 25 cm for 10 s. Subsequently, the sample solution was injected at a height of 25 cm for 480 s, after which a voltage of -20 kV was applied and the sample stacking was initiated. The stacking process was completed when 95 % of the separation current was attained. Under optimized conditions, the contraction folds of the four barbiturate analytes (R, S-Secobarbital, R, S-pentobarbital) were improved by approximately 6400-fold, achieving detection limits of 0.1 ng/mL. The limits of quantification for all analyte enantiomers were 0.5-50 ng/mL, demonstrating good linearity (r > 0.997). Migration times exhibited a relative standard deviation of less than 1.7 %, whereas peak areas for the four analytes exhibited a deviation of 8.7 %. Finally, the established method was effectively applied to the analysis of human serum samples.
Asunto(s)
Barbitúricos , Electroforesis Capilar , Límite de Detección , Microextracción en Fase Líquida , Electroforesis Capilar/métodos , Microextracción en Fase Líquida/métodos , Estereoisomerismo , Humanos , Barbitúricos/sangre , Barbitúricos/química , Reproducibilidad de los ResultadosRESUMEN
Daprodustat is a prolyl hydroxylase inhibitor that stimulates erythropoiesis in a manner similar to the natural response to hypoxia, whereby inhibition of hypoxia inducible factor (HIF) prolyl-4-hydroxylases by daprodustat ultimately results in increased levels of HIF-responsive genes. Daprodustat is under development as an emerging new class of agents for the treatment of anemia associated with chronic kidney disease (CKD). This was a single-center, single-dose, open-label, randomized, 2-way crossover study in healthy Japanese male participants consisting of 2 parts. The primary objective was to evaluate the bioequivalence (BE) between daprodustat tablet strengths (part 1) and to evaluate the food effect on the pharmacokinetics (PK) of daprodustat (part 2). A total of 64 healthy Japanese male participants were enrolled; 52 participants were included in part 1 and 12 in part 2. BE was demonstrated between the daprodustat 2-mg tablet and the daprodustat 4-mg tablet. A standard CKD meal did not have a large effect on the PK parameters of daprodustat after a single oral dose of daprodustat 4 mg. Administration of single oral doses of daprodustat 4 mg was generally well tolerated in the healthy Japanese participants, and no new safety signals were identified without regard to food.
Asunto(s)
Anemia/tratamiento farmacológico , Barbitúricos/farmacocinética , Glicina/análogos & derivados , Voluntarios Sanos/estadística & datos numéricos , Inhibidores de Prolil-Hidroxilasa/farmacocinética , Equivalencia Terapéutica , Administración Oral , Adulto , Anemia/etiología , Área Bajo la Curva , Pueblo Asiatico/etnología , Barbitúricos/administración & dosificación , Barbitúricos/efectos adversos , Barbitúricos/sangre , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Eritropoyesis/efectos de los fármacos , Interacciones Alimento-Droga/fisiología , Glicina/administración & dosificación , Glicina/efectos adversos , Glicina/sangre , Glicina/farmacocinética , Humanos , Masculino , Preparaciones Farmacéuticas/provisión & distribución , Inhibidores de Prolil-Hidroxilasa/administración & dosificación , Inhibidores de Prolil-Hidroxilasa/efectos adversos , Inhibidores de Prolil-Hidroxilasa/sangre , Insuficiencia Renal Crónica/complicaciones , SeguridadRESUMEN
Objective In the management of patients with suspected acute drug poisoning, a screening test using the patient's urine is usually performed. The Triage DOA® and INSTANT-VIEW M-1® kits are two commonly used point-of-care screening kits in Japan. However, the relationship between the results of these screening kits and the blood concentration of the poisoning drug is not clear. In this study, we evaluated which kit is more useful for acute drug poisoning screening based on a comparison of their results with the results of a serum drug analysis. Methods This prospective cross-sectional study investigated all patients with acute drug poisoning admitted to a general hospital in Tokyo, Japan, over a nine-month period. The Triage DOA® and INSTANT-VIEW M-1® screening kits were used, and a qualitative serum analysis was conducted simultaneously in all cases. We compared the kits for use in screening patients with acute drug poisoning and evaluated the utility of the kits. Results For the 117 patients enrolled in this study, the 2 kits showed different sensitivities to benzodiazepines (Triage®, 78.6%; INSTANT-VIEW®, 90.5%). Both kits showed high sensitivity to barbiturates (Triage®, 87.0%; INSTANT-VIEW®, 91.3%) but low sensitivity to tricyclic antidepressants (Triage®, 25.0%; INSTANT-VIEW®, 45.8%). Conclusion Because the sensitivity varies depending on the kind of drug, it is difficult to discuss the superiority of these kits. However, this study compared the results of two types of urinary drug screening kits with the results of qualitative analysis of drugs in serum as a gold standard, providing important reference data.
Asunto(s)
Tamizaje Masivo/métodos , Juego de Reactivos para Diagnóstico , Trastornos Relacionados con Sustancias/sangre , Trastornos Relacionados con Sustancias/orina , Triaje/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antidepresivos Tricíclicos/sangre , Antidepresivos Tricíclicos/orina , Barbitúricos/sangre , Barbitúricos/orina , Benzodiazepinas/sangre , Benzodiazepinas/orina , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Tokio , Adulto JovenRESUMEN
Comprehensive drug-screening performed by liquid chromatography-high resolution mass spectrometry (LC-HRMS) enables identification of hundreds to thousands of drug compounds in a single analysis. Forensic drug screening is generally performed with positive electrospray ionization (ESI+ ), targeting basic drugs; however, a few toxicologically important drugs such as barbiturates, may require analysis by negative ESI. In this work, screening targets for barbiturates were determined using our LC-HRMS screening with ESI+ . For several years, our forensic whole blood samples have been analyzed using the LC-HRMS-ESI+ screening in parallel with a multi-target LC-MS/MS-ESI- method. From 2014 to 2018, 23 samples were positive for phenobarbital (0.5-81 mg/kg). Retrospective data analysis of 4816 blood samples (15 positive) revealed several potential screening targets for phenobarbital. The targets were tentatively identified by exact mass and isotopic pattern as uncommon adducts of phenobarbital and as a decomposition product of phenobarbital N-glucoside (C17 H24 N2 O7 ). Analysis of a test set containing eight positive (0.5-65 mg/kg phenobarbital) and 31 negative samples supported the use of the observed target m/z 323.0614 at 5.14 minutes, corresponding to the [M + HCOONa+Na]+ adduct of phenobarbital. The [M + HCOONa+Na]+ adduct was confirmed as a screening target for common barbiturates, by analysis of barbiturate reference standards in ESI+ /ESI- . The [M + HCOONa+Na]+ adduct allowed retrospective analysis with 91% sensitivity (n = 23) and 100% specificity (n = 4855) for phenobarbital in our existing LC-HRMS-ESI+ screening. The two negative results were the two whole-blood samples with the lowest phenobarbital concentration (<1.8 mg/kg). Thus, a specialized screening is not necessary and use of this adduct likely enables screening for other barbiturates.
Asunto(s)
Barbitúricos/sangre , Hipnóticos y Sedantes/sangre , Fenobarbital/sangre , Espectrometría de Masa por Ionización de Electrospray/métodos , Cromatografía Líquida de Alta Presión/métodos , Medicina Legal/métodos , Humanos , Límite de Detección , Espectrometría de Masas en Tándem/métodosRESUMEN
Zoliflodacin is a novel spiropyrimidinetrione with activity against bacterial type II topoisomerases that inhibits DNA biosynthesis and results in accumulation of double-strand cleavages in bacteria. We report results from two phase 1 studies that investigated the safety, tolerability, and pharmacokinetics (PK) of zoliflodacin and absorption, distribution, metabolism, and excretion (ADME) after single doses in healthy volunteers. In the single ascending dose study, zoliflodacin was rapidly absorbed, with a time to maximum concentration of drug in serum (Tmax) between 1.5 and 2.3 h. Exposure increased dose proportionally up to 800 mg and less than dose proportionally between 800 and 4,000 mg. Urinary excretion of unchanged zoliflodacin was <5.0% of the total dose. In the fed state, absorption was delayed (Tmax, 4 h), accompanied by an increase in the area under the concentration-time curve (AUC) at 1,500- and 3,000-mg doses. In the ADME study (3,000 mg orally), the PK profile of zoliflodacin had exposure (AUC and maximum concentration of drug in serum [Cmax]) similar to that of the ascending dose study and a median Tmax of 2.5 h. A total of 97.8% of the administered radioactivity was recovered in excreta, with urine and fecal elimination accounting for approximately 18.2% and 79.6% of the dose, respectively. The major clearance pathway was via metabolism and elimination in feces with low urinary recovery of unchanged drug (approximately 2.5%) and metabolites accounting for 56% of the dose excreted in the feces. Zoliflodacin represented 72.3% and metabolite M3 accounted for 16.4% of total circulating radioactivity in human plasma. Along with the results from these studies and based upon safety, PK, and PK/pharmacodynamics targets, a dosage regimen was selected for evaluation in a phase 2 study in urogenital gonorrhea. (The studies discussed in this paper have been registered at ClinicalTrials.gov under identifiers NCT01929629 and NCT02298920.).
Asunto(s)
Antibacterianos/farmacocinética , Barbitúricos/farmacocinética , Compuestos de Espiro/farmacocinética , Adulto , Antibacterianos/sangre , Antibacterianos/orina , Área Bajo la Curva , Barbitúricos/sangre , Barbitúricos/orina , Disponibilidad Biológica , Biotransformación , Esquema de Medicación , Heces/microbiología , Femenino , Absorción Gastrointestinal/fisiología , Semivida , Voluntarios Sanos , Humanos , Isoxazoles , Masculino , Morfolinas , Oxazolidinonas , Compuestos de Espiro/sangre , Compuestos de Espiro/orinaRESUMEN
This study was conducted to evaluate the likelihood of daprodustat to act as a perpetrator in drug-drug interactions (DDI) with the CYP2C8 enzyme and OATP1B1 transporter using the probe substrates pioglitazone and rosuvastatin as potential victims, respectively. Additionally, this study assessed the effect of a weak CYP2C8 inhibitor, trimethoprim, as a perpetrator of a DDI with daprodustat. This was a two-part study: Part A assessed the effect of coadministration of daprodustat on the pharmacokinetics of pioglitazone and rosuvastatin in 20 subjects; Part B assessed the coadministration of trimethoprim on the pharmacokinetics of daprodustat in 20 subjects. Coadministration of 100 mg of daprodustat with pioglitazone or rosuvastatin had no effect on the plasma exposures of either probe substrate. When trimethoprim was coadministered with 25-mg daprodustat plasma daprodustat AUC and Cmax increased by 48% and 28%, respectively. Additionally, AUC and Cmax for the metabolite GSK2531401 were decreased by 32% and 40%, respectively. Cmax for the other metabolites was slightly decreased (~8-15%) but no changes in AUC were observed. As 100-mg daprodustat exceeds the planned top therapeutic dose, interaction potential of daprodustat as a perpetrator with substrates of the CYP2C8 enzyme and OATP1B1 transporters is very low. Conversely, daprodustat exposure (AUC and Cmax) is likely to increase moderately with coadministration of weak CYP2C8 inhibitors.
Asunto(s)
Barbitúricos/farmacología , Citocromo P-450 CYP2C8/metabolismo , Glicina/análogos & derivados , Transportador 1 de Anión Orgánico Específico del Hígado/metabolismo , Rosuvastatina Cálcica/sangre , Tiazolidinedionas/sangre , Trimetoprim/sangre , Administración Oral , Barbitúricos/administración & dosificación , Barbitúricos/sangre , Estudios Cruzados , Interacciones Farmacológicas , Femenino , Glicina/administración & dosificación , Glicina/sangre , Glicina/farmacología , Voluntarios Sanos , Humanos , Masculino , Pioglitazona , Rosuvastatina Cálcica/administración & dosificación , Especificidad por Sustrato , Tiazolidinedionas/administración & dosificación , Trimetoprim/administración & dosificación , Trimetoprim/farmacologíaRESUMEN
BACKGROUND: Butalbital is a small molecule (approximately 220 Da), with 26% protein binding, a 0.8 L/kg volume of distribution, and is eliminated nearly 80% unchanged in the urine. Although hemodialysis has been used to treat overdoses of other barbiturates, the extracorporeal clearance of butalbital is unknown. The objective of this case is to describe the use of extracorporeal therapy to augment elimination of butalbital after an overdose of aspirin 325 mg-butalbital 50 mg-caffeine 40 mg with codeine 30 mg (Fiorinal with Codeine). METHODS: This is a case report of a single patient. RESULTS: A 67-year-old female was admitted to the medical intensive care unit approximately 3 h after ingestion of 40 tablets of Fiorinal with Codeine. Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L). Approximately 8 h after ingestion of 2000 mg of butalbital, our patient's serum concentration was 26.9 mg/L (normal <10 mg/L). At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min. CONCLUSIONS: The extracorporeal clearance of butalbital observed in this case demonstrates the utility of dialysis to augment drug elimination in a Fiorinal with Codeine overdose.
Asunto(s)
Aspirina/envenenamiento , Barbitúricos/envenenamiento , Cafeína/envenenamiento , Codeína/envenenamiento , Diálisis Renal , Anciano , Barbitúricos/sangre , Combinación de Medicamentos , Femenino , HumanosRESUMEN
A 15-year-old female subject presented comatose, in respiratory failure and shock, after the intentional ingestion of â¼280 extended-release 200-mg carbamazepine tablets with a peak serum concentration of 138 µg/mL (583.74 µmol/L). The patient developed clinical seizures and an EEG pattern of stimulus-induced rhythmic, periodic, or ictal discharges, suggestive of significant cortical dysfunction. Due to the extremely high drug serum concentration and clinical instability, a combination of therapies was used, including lipid emulsion therapy, plasmapheresis, hemodialysis, continuous venovenous hemodiafiltration, and endoscopic intestinal decontamination. The patient's elevated serum lactate level with a high mixed venous saturation suggested possible mitochondrial dysfunction, prompting treatment with barbiturate coma to reduce cerebral metabolic demand. The serum carbamazepine concentration declined steadily, with resolution of lactic acidosis, no long-term end-organ damage, and return to baseline neurologic function. The patient was eventually discharged in her usual state of health. In the laboratory, we demonstrated in vitro that the active metabolite of carbamazepine hyperpolarized the mitochondrial membrane potential, supporting the hypothesis that the drug caused mitochondrial dysfunction. We thus successfully treated a life-threatening carbamazepine overdose with a combination of modalities. Future studies are required to validate this aggressive approach. The occurrence of mitochondrial dysfunction must be confirmed in patients with carbamazepine toxicity and the need to treat it validated.
Asunto(s)
Barbitúricos/envenenamiento , Carbamazepina/envenenamiento , Coma/inducido químicamente , Terapia Combinada/métodos , Sobredosis de Droga/terapia , Adolescente , Barbitúricos/sangre , Carbamazepina/sangre , Coma/terapia , Descontaminación/métodos , Femenino , Hemodiafiltración/métodos , Humanos , Plasmaféresis/métodos , Diálisis Renal/métodosRESUMEN
A rapid and sensitive method for simultaneous screening, quantification and confirmation of 17 barbiturates in horse plasma using liquid chromatography-tandem mass spectrometry is described. Analytes were recovered from plasma by liquid-liquid extraction using methyl tert-butyl ether, separated on a C18 column, and analyzed in negative electrospray ionization mode. Multiple-reaction monitoring was employed for screening and quantification. Confirmation for the presence of the analytes was achieved by comparing ion intensity ratio. The ranges for limits of detection, quantification and confirmation were 0.003-1 ng/mL (S/N ≥ 3), 0.01-2.5 ng/mL and 0.02-5 ng/mL, respectively. The linear dynamic range of the method was 0.1-100 ng/mL. The precision and accuracy at 0.5, 5 and 50 ng/mL of all 17 barbiturates during intra-day assay were 1.6-8.6% and 96-106%, respectively. For inter-day assay, precision and accuracy at the same three concentrations were 2.6-8.9% and 96-106%, respectively. Analysis of all 17 analytes was completed within 7 min. Thus, the present method is fast, simple, sensitive and reproducibly reliable.
Asunto(s)
Barbitúricos/sangre , Doping en los Deportes , Detección de Abuso de Sustancias/métodos , Animales , Caballos , Extracción Líquido-Líquido , Éteres Metílicos , PlasmaRESUMEN
A rapid, simple and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the qualitative and quantitative analysis of nine barbiturates (barbital, phenobarbital, pentobarbital, amobarbital, secobarbital, thiopental, butalbital, butabarbital, and hexobarbital) in human whole blood. Barbiturates were extracted from 100 µL of human whole blood samples using a simple liquid-liquid extraction (LLE) procedure, and detected by LC-MS/MS. An UPLC C18 (2.1 mm × 100 mm, 1.7 µm) column was used at 40 °C for the separation and acetonitrile/water system was used as the mobile phase with gradient elution. This method showed excellent accuracy (86-111%) and precision (relative standard deviation <15%). The limits of detection (LODs) were 0.2 ng/mL for barbital and secobarbital and 0.5 ng/mL for the other barbiturates. The linearity ranged from 2 ng/mL to 2000 ng/mL, with r2 > 0.99 over the range. This method achieved the separation and detection of pentobarbital and amobarbital at the same time in a convenient way. Moreover, it was both simple and sensitive for the determination of nine most commonly used barbiturate drugs, which was meaningful in the field of clinical and forensic toxicology. Copyright © 2016 John Wiley & Sons, Ltd.
Asunto(s)
Barbitúricos/sangre , Cromatografía Liquida/métodos , Hipnóticos y Sedantes/sangre , Espectrometría de Masas en Tándem/métodos , Cromatografía Liquida/economía , Toxicología Forense/economía , Toxicología Forense/métodos , Humanos , Límite de Detección , Masculino , Persona de Mediana Edad , Detección de Abuso de Sustancias/economía , Detección de Abuso de Sustancias/métodos , Espectrometría de Masas en Tándem/economía , Factores de TiempoRESUMEN
GSK1278863 is an investigative drug under investigation for treatment of anemia associated with chronic kidney disease. Its metabolism is primarily metabolized by P450 enzymes where 19 unique metabolic species have been identified. These include multiple products of mono-, di-, and tri-oxygenation. Initially, two separate and complex ultra high performance liquid chromatography (UHPLC) reverse phase methodologies were developed, validated and applied to measure parent and various predominant and circulating metabolites in numerous clinical studies. However, 5 of the 6 oxidative metabolites may exist in different stereoisomeric forms, resulting in 14 separate species; therefore a chiral methodology was required to determine which stereoisomeric forms circulated in human. A variety of conventional approaches were explored, where in the end a supercritical fluid chromatography (SFC) method was required to separate this complex mixture of 14 stereoisomeric metabolites; data from these experiments provided important information on which species circulate in human. The details of these methodologies will be discussed herein.
Asunto(s)
Barbitúricos/sangre , Cromatografía Líquida de Alta Presión/métodos , Cromatografía con Fluido Supercrítico/métodos , Glicina/análogos & derivados , Inhibidores de Prolil-Hidroxilasa/sangre , Barbitúricos/aislamiento & purificación , Barbitúricos/metabolismo , Cromatografía de Fase Inversa/métodos , Sistema Enzimático del Citocromo P-450/metabolismo , Glicina/sangre , Glicina/aislamiento & purificación , Glicina/metabolismo , Humanos , Oxidación-Reducción , Inhibidores de Prolil-Hidroxilasa/aislamiento & purificación , Inhibidores de Prolil-Hidroxilasa/metabolismo , Reproducibilidad de los Resultados , EstereoisomerismoRESUMEN
This study was performed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of GSK1278863, a novel prolyl hydroxylase inhibitor, following a single oral administration of GSK1278863 from 10 to 100 mg or placebo in Japanese (n = 19), and 10, 25 and 100 mg in Caucasians (n = 14). Dose-proportional increases were observed in AUCinf of GSK1278863 in both ethnic groups, with a 1.3-1.5-fold higher exposure seen in Japanese relative to Caucasians for all doses. This difference in exposure can be mainly explained by the observed differences in body weights between the two groups. Statistically significant increases in erythropoietin (EPO), vascular endothelial growth factor (VEGF) and reticulocyte counts were observed in Japanese subjects after the 50 and 100 mg dose as compared to placebo. In Caucasians, similar to Japanese, EPO and VEGF levels were observed to be increased in response to the 100 mg dose. Drug-related adverse events, including headache and abdominal pain were reported in 3 Japanese subjects, while headache was reported in 3 Caucasians. In conclusion, GSK1278863 was well tolerated, with dose-proportional increases in exposure observed in both groups. There was no evidence of ethnic differences between Japanese and Caucasian with regard to PK or PD.
Asunto(s)
Pueblo Asiatico , Barbitúricos/administración & dosificación , Barbitúricos/farmacocinética , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacocinética , Glicina/análogos & derivados , Prolina Dioxigenasas del Factor Inducible por Hipoxia/antagonistas & inhibidores , Población Blanca , Administración Oral , Adulto , Área Bajo la Curva , Barbitúricos/efectos adversos , Barbitúricos/sangre , Peso Corporal/etnología , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/efectos adversos , Inhibidores Enzimáticos/sangre , Eritropoyetina/sangre , Glicina/administración & dosificación , Glicina/efectos adversos , Glicina/sangre , Glicina/farmacocinética , Semivida , Voluntarios Sanos , Humanos , Prolina Dioxigenasas del Factor Inducible por Hipoxia/metabolismo , Japón , Masculino , Tasa de Depuración Metabólica , Reticulocitos/efectos de los fármacos , Reticulocitos/metabolismo , Método Simple Ciego , Factor A de Crecimiento Endotelial Vascular/sangre , Adulto JovenRESUMEN
Butalbital, a barbiturate, is present in analgesic combinations used by headache sufferers. Overuse/abuse of these combinations may cause dependence, chronic migraine, and medication-overuse headache (MOH). MOH is difficult to manage: it improves interrupting analgesic overuse, but requires monitoring, because relapses are frequent. A gas chromatography-mass spectrometry (GC-MS) method for hair analysis has been developed and validated to document abuse of an analgesic combination containing butalbital and propyphenazone by a patient with MOH. For over ten years the patient managed her headache using eight suppositories/day of an analgesic combination containing butalbital 150mg, caffeine 75mg, and propyphenazone 375mg per suppository. An outpatient detoxification treatment was carried out. After three weeks, the patient reduced the consumption to one suppository/day. At the first control visit, after three months from the beginning of detoxification, the patient increased the use of the combination to four suppositories/day and at the second control visit, after seven months from the beginning of detoxification, she was back to eight suppositories/day. At the two control visits, a hair sample was taken for determination of butalbital and propyphenazone. Moreover blood and urine samples for determination of butalbital were drawn at the beginning of detoxification treatment and at the two control visits. With the segmental analysis of two hair samples the medication history of ten months could be estimated. In the first hair sample, collected at the first control visit, in the distal segment, butalbital and propyphenazone concentrations were, respectively, 17.5ng/mg and 56.0ng/mg, confirming the prolonged abuse; in the proximal segment, concurrently with the detoxification treatment, butalbital and propyphenazone concentrations had reduced respectively to 5.45ng/mg and 11.1ng/mg. The second hair sample, collected at the second control visit, proved the fair course of the detoxification treatment in the distal segment and signalled relapse in the abuse of the analgesic combination in the proximal segment. In the clinical context, hair analysis can be advantageously used to monitor the abuse of analgesic combinations with butalbital, common among headache patients. The validation data showed that GC-MS method developed for determination of butalbital and propyphenazone was rapid, highly sensitive, specific and selective.
Asunto(s)
Analgésicos/metabolismo , Antipirina/análogos & derivados , Barbitúricos/metabolismo , Cromatografía de Gases y Espectrometría de Masas , Cabello/metabolismo , Cefaleas Secundarias/diagnóstico , Detección de Abuso de Sustancias/métodos , Trastornos Relacionados con Sustancias/diagnóstico , Anciano , Analgésicos/sangre , Analgésicos/orina , Antipirina/metabolismo , Barbitúricos/sangre , Barbitúricos/orina , Combinación de Medicamentos , Femenino , Cefaleas Secundarias/metabolismo , Cefaleas Secundarias/terapia , Humanos , Valor Predictivo de las Pruebas , Recurrencia , Reproducibilidad de los Resultados , Trastornos Relacionados con Sustancias/metabolismo , Trastornos Relacionados con Sustancias/terapia , Factores de TiempoRESUMEN
An evaluation of an internal laboratory decision to implement a protocol for limiting drug testing based on ethanol concentration in laboratory analysis for driving under the influence (DUI) cases is presented. The described case management strategy is supported by known impairment of ethanol at relatively high concentrations, difficulty assigning a level of contributing impairment from drugs in the presence of high ethanol levels and the likelihood that the drug results may be suppressed at trial. Although the results of this study reinforce the assertion that such protocols lead to the under reporting of drugs in DUI cases, for the majority of cases, 95% in this study, the drug analysis results were not significant and did not warrant the time and resources needed for the additional blood drug testing. Furthermore, the study demonstrated that a high drug positivity rate does not necessarily mean that those drug results are legally or pharmacologically meaningful. Additional research should be conducted with quantitative drug results and casework impact of blood drug screen protocols as previous studies only report drug positivity rates and not whether the drug results would be meaningful to the case.
Asunto(s)
Conducción de Automóvil , Etanol/sangre , Toxicología Forense/organización & administración , Detección de Abuso de Sustancias/métodos , Barbitúricos/sangre , Benzodiazepinas/sangre , Carisoprodol/sangre , Cocaína/análogos & derivados , Cocaína/sangre , Dronabinol/sangre , Cromatografía de Gases y Espectrometría de Masas , Humanos , Metanfetamina/sangre , Oxicodona/sangre , Oximorfona/sangreRESUMEN
In December 2012, the possession and private use of limited quantities of marijuana and marijuana products became legal in the state of Washington. At the same time, the state's driving under the influence statutes were amended to include a per se level of 5 ng/mL delta(9)-tetrahydrocannabinol (THC) in whole blood for drivers aged 21 years and older. The aim of this study was to assess the effect of marijuana legalization on the prevalence of marijuana in suspected impaired driving cases. The prevalence of both active THC and its metabolite carboxy-THC detected in such cases pre-legalization was compared with the prevalence post-legalization. In 2009-2012, the average yearly percentage of cases positive for THC and carboxy-THC was 19.1% (range: 18.2-20.2%) and 27.9% (range: 26.3-28.6%), respectively. In 2013, the percentages had significantly increased to 24.9 and 40.0%, respectively (P < 0.05). The median THC concentration over the 5-year period ranged from 5.2 to 6.3 ng/mL, with individual concentrations ranging up to 90 ng/mL. An average of 56% of cases were at or >5 ng/mL over the 5-year period. The prevalence of alcohol and the majority of other drugs in this same population of suspected impaired drivers submitted for testing did not change during this same 5-year period-marijuana was the only drug to show such an increase in frequency. Further, this observed increase remained after the data had been normalized to account for changes in laboratory testing procedures that occurred during this time period. Future studies need be conducted to ascertain whether the observed increase has had any effect on the incidence of crashes, serious injuries and/or traffic fatalities.
Asunto(s)
Conducción de Automóvil , Cannabis/química , Detección de Abuso de Sustancias/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anfetaminas/sangre , Antidepresivos Tricíclicos/sangre , Barbitúricos/sangre , Benzodiazepinas/sangre , Cannabinoides/sangre , Cocaína/sangre , Dextropropoxifeno/sangre , Femenino , Humanos , Masculino , Metadona/sangre , Persona de Mediana Edad , Fenciclidina/sangre , Washingtón , Adulto JovenAsunto(s)
Intoxicación/sangre , Intoxicación/diagnóstico , Acetaminofén/sangre , Acetaminofén/envenenamiento , Aspirina/sangre , Aspirina/envenenamiento , Barbitúricos/sangre , Barbitúricos/envenenamiento , Digoxina/sangre , Digoxina/envenenamiento , Monitoreo de Drogas , Humanos , Compuestos Inorgánicos/sangre , Compuestos Inorgánicos/envenenamiento , Litio/sangre , Litio/envenenamiento , Compuestos Orgánicos/sangre , Compuestos Orgánicos/envenenamiento , Plaguicidas/sangre , Plaguicidas/envenenamiento , Intoxicación/terapia , Teofilina/sangre , Teofilina/envenenamientoRESUMEN
Nowadays traffic accidents, which have high mortality and morbidity, are an important public health problem. The association between the use of alcohol and/or drugs by drivers and the increased risk of traffic accidents with a high risk of death and injury has been well described in the literature. This study aimed to review the incidence of cases of driving under the influence of drugs (DUID) among all cases of driving under the influence (DUI) of alcohol and/or other drugs involved in traffic accidents and to evaluate the type of the psychoactive drugs (with or without alcohol) detected in blood samples in Istanbul and its surrounding area. This study is the first investigation on the subject of DUID cases in Turkey. The reports of the Istanbul Toxicology Department of the Council of Forensic Medicine (Turkey) on suspected DUID cases involved in traffic accidents between 1 July 2010 and 30 June 2011 were retrospectively reviewed for alcohol and/or drug use. Alcohol analysis was requested in 4274 suspected DUI cases, whereas drug along with alcohol analysis was requested in only 91. The rate of suspected DUID cases (n = 91) among the suspected DUI cases (n = 4274) was only 2.1% and in this study, we evaluated only the DUID cases in detail. Alcohol was present in 44% of suspected DUID cases. Psychoactive drugs were present in 15.4% of cases. The incidence among 46 confirmed DUID cases was found to be 17.4% for cannabis, 8.7% for benzodiazepines, 4.3% for barbiturates, 4.3% for antidepressants, 2.2% for cocaine and 2.2% for amphetamines. Although there is a zero-tolerance approach for DUID in the Turkish regulations, it is not well recognised and not inspected by police and legal authorities who are responsible for taking measures in traffic accidents and for routine traffic controls in Turkey. It is concluded that psychoactive drugs should be checked as well as alcohol in all traffic accident cases and roadside controls.
Asunto(s)
Accidentes de Tránsito/estadística & datos numéricos , Conducción de Automóvil , Trastornos Relacionados con Sustancias/epidemiología , Adolescente , Adulto , Anfetaminas/sangre , Antidepresivos/sangre , Barbitúricos/sangre , Benzodiazepinas/sangre , Cannabinoides/sangre , Depresores del Sistema Nervioso Central/sangre , Cromatografía de Gases , Cromatografía Liquida , Cocaína/sangre , Etanol/sangre , Femenino , Toxicología Forense , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Trastornos Relacionados con Sustancias/sangre , Espectrometría de Masas en Tándem , Turquía , Adulto JovenRESUMEN
Butalbital (Fiorinal(®)), used in the treatment of migraines and muscle pain, is the most commonly encountered barbiturate in impaired driving cases. It has central nervous system (CNS) depressant properties, including sedation, drowsiness, and feelings of intoxication, which can contribute to driving impairment. Twenty-six driving under the influence cases are reviewed including results from field sobriety tests and toxicology testing. Blood samples were screened using enzyme multiplied immunoassay technique immunoassay, and the presence of butalbital was confirmed and quantified using gas chromatography/mass spectrometry, gas chromatography with flame ionization detection, or gas chromatography nitrogen/phosphorus detection. Butalbital concentrations ranged from 1.0 to 30.2 mg/L, with a mean and median of 16.0 mg/L. General impairment indicators in these cases included horizontal and vertical nystagmus, lack of convergence, poor motor coordination, and balance and speech problems, which are common to CNS depressant intoxication, similar to that associated with alcohol. These findings indicate the importance of toxicological testing for butalbital in cases where CNS depressants are indicated.
Asunto(s)
Conducción de Automóvil/legislación & jurisprudencia , Barbitúricos/efectos adversos , Adulto , Ataxia/inducido químicamente , Barbitúricos/sangre , Femenino , Toxicología Forense , Cromatografía de Gases y Espectrometría de Masas , Humanos , Inmunoensayo , Aplicación de la Ley , Masculino , Persona de Mediana Edad , Nistagmo Patológico/inducido químicamente , Equilibrio Postural/efectos de los fármacos , Trastornos del Habla/inducido químicamenteRESUMEN
OBJECTIVE: Physician suicide is an important public health problem as the rate of suicide is higher among physicians than the general population. Unfortunately, few studies have evaluated information about mental health comorbidities and psychosocial stressors which may contribute to physician suicide. We sought to evaluate these factors among physicians versus non-physician suicide victims. METHODS: We used data from the United States National Violent Death Reporting System to evaluate demographics, mental health variables, recent stressors and suicide methods among physician versus non-physician suicide victims in 17 states. RESULTS: The data set included 31,636 suicide victims of whom 203 were identified as physicians. Multivariable logistic regression found that having a known mental health disorder or a job problem which contributed to the suicide significantly predicted being a physician. Physicians were significantly more likely than non-physicians to have antipsychotics, benzodiazepines and barbiturates present on toxicology testing but not antidepressants. CONCLUSIONS: Mental illness is an important comorbidity for physicians who complete a suicide but postmortem toxicology data shows low rates of medication treatment. Inadequate treatment and increased problems related to job stress may be potentially modifiable risk factors to reduce suicidal death among physicians.
Asunto(s)
Trastornos Mentales/epidemiología , Médicos/estadística & datos numéricos , Suicidio/estadística & datos numéricos , Adulto , Anciano , Antipsicóticos/sangre , Asfixia/epidemiología , Barbitúricos/sangre , Benzodiazepinas/sangre , Causas de Muerte , Depresión/epidemiología , Sobredosis de Droga/epidemiología , Femenino , Armas de Fuego/estadística & datos numéricos , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Médicos/psicología , Estudios Retrospectivos , Suicidio/psicología , Estados Unidos/epidemiología , Heridas no Penetrantes/epidemiologíaRESUMEN
Here, we present a method for measuring barbiturates (butalbital, secobarbital, pentobarbital, and phenobarbital) in whole blood samples. To accomplish these measurements, analytes were extracted by means of hollow-fiber liquid-phase microextraction in the three-phase mode. Hollow-fiber pores were filled with decanol, and a solution of sodium hydroxide (pH 13) was introduced into the lumen of the fiber (acceptor phase). The fiber was submersed in the acidified blood sample, and the system was subjected to an ultrasonic bath. After a 5 min extraction, the acceptor phase was withdrawn from the fiber and dried under a nitrogen stream. The residue was reconstituted with ethyl acetate and trimethylanilinium hydroxide. An aliquot of 1.0 µL of this solution was injected into the gas chromatograph/mass spectrometer, with the derivatization reaction occurring in the hot injector port (flash methylation). The method proved to be simple and rapid, and only a small amount of organic solvent (decanol) was needed for extraction. The detection limit was 0.5 µg/mL for all the analyzed barbiturates. The calibration curves were linear over the specified range (1.0 to 10.0 µg/mL). This method was successfully applied to postmortem samples (heart blood and femoral blood) collected from three deceased persons previously exposed to barbiturates.